Ratings for Dentsply Sirona (NASDAQ:XRAY) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 2 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Dentsply Sirona, presenting an average target of $20.75, a high estimate of $25.00, and a low estimate of $16.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 5.68%.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive Dentsply Sirona is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Michael Petusky | Barrington Research | Maintains | Outperform | $21.00 | $21.00 |
| Michael Petusky | Barrington Research | Raises | Outperform | $21.00 | $20.00 |
| Kevin Caliendo | UBS | Lowers | Buy | $25.00 | $27.00 |
| Jason Bednar | Piper Sandler | Lowers | Neutral | $16.00 | $20.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Dentsply Sirona. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Dentsply Sirona compared to the broader market.
- Price Targets: Delving into movements, analysts provide estimates for the future value of Dentsply Sirona's stock. This analysis reveals shifts in analysts' expectations over time.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Dentsply Sirona's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Dentsply Sirona analyst ratings.
Unveiling the Story Behind Dentsply Sirona
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
Dentsply Sirona: Delving into Financials
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Dentsply Sirona's revenue growth over a period of 3M has faced challenges. As of 31 March, 2025, the company experienced a revenue decline of approximately -7.76%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's net margin excels beyond industry benchmarks, reaching 2.28%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dentsply Sirona's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 1.01%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Dentsply Sirona's ROA stands out, surpassing industry averages. With an impressive ROA of 0.34%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Dentsply Sirona's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.21, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Understanding the Relevance of Analyst Ratings
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Latest Ratings for XRAY
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 2025 | Barrington Research | Reiterates | Outperform | Outperform |
| Jul 2025 | Needham | Reiterates | Hold | Hold |
| May 2025 | Barrington Research | Maintains | Outperform | Outperform |
View More Analyst Ratings for XRAY
View the Latest Analyst Ratings
© 2025 Benzinga.com. Benzinga does not provideinvestment advice All rights reserved.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
